• Mustafa Yilmaz, Omer Ozütemiz, Zeki Karasu, Galip Ersöz, Fulya Günsar, Yücel Batur, Ahmet Aydin, Oktay Tekesin, Nadir Yönetci, and Tankut Ilter.
• Department of Gastroenterology, School of Medicine, Pamukkale University, Denizli, Turkey. kmustyil@yahoo.com
• Hepato Gastroenterol. 2005 Sep 1;52(65):1622-5.

Background/AimsDieulafoy's lesion is a rare cause of upper gastrointestinal bleeding and is potentially life threatening. The aim of this study is to determine the clinical features of these lesions and the efficacy of the endoscopic injection sclerotherapy in patients with Dieulafoy's lesion.MethodologyBetween January 1994 and December 2001, twenty-eight patients with upper gastrointestinal bleeding due to Dieulafoy's lesion were treated by endoscopic injection sclerotherapy. Efficacy of endoscopic therapy and clinical findings of these cases were analyzed.ResultsThe study group consisted of 22 male (78.5%) and 6 female (21.5%) patients with a mean age of 57 years (range 22-82 years). Significant comorbidity was present in 22 (78.5%) patients. Hemoglobin values of the patients ranged from 5.4-10.3 g/dL at hospitalization. The median transfusion requirement was 5 (range 0-12) units. Dieulafoy's lesion was observed in the proximal half of stomach in 25 cases (89.3%), in the antrum in 2 cases (7.1%) and in the angulus in 1 case (3.5%). Endoscopic injection sclerotherapy was successful in stopping the bleeding in 26 out of 28 patients (92.8%).ConclusionsDieulafoy's lesions mostly affect the proximal stomach and cause serious upper gastrointestinal bleeding. Endoscopic injection sclerotherapy is an effective and a safe therapeutic method for Dieulafoy's lesion.

16 keywords...

hide…